News
First-of-its kind guideline on lipid monitoring in endocrine diseases
November 6, 2020
A new guideline from the Endocrine Society calls for heightened awareness of cholesterol management and treatment in endocrine diseases beyond diabetes; the aim is to make lipid panel routine in assessment.
News
Consensus guidelines address inpatient diabetes technology
October 29, 2020
The comprehensive document aimed at clinicians, hospitals, and researchers covers use of both continuous glucose monitors and automated insulin dosing systems in the hospital setting.
News
COVID-19 antibody response not reduced with diabetes
October 20, 2020
Findings provide “cautious optimism” that a COVID-19 vaccine would be expected to work as well in people with diabetes as those without.
News
Entresto halves renal events in preserved EF heart failure patients
October 15, 2020
The PARAGON-HF trial of sacubitril/valsartan in patients with heart failure with preserved ejection fraction didn’t meet its primary outcome but significantly improved a secondary renal endpoint.
![1]()
News
Empagliflozin cut PA pressures in heart failure patients
October 12, 2020
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time.
![1]()
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
October 6, 2020
Empagliflozin treatment of HFrEF was equally beneficial regardless of whether patients also received sacubitril/valsartan.
![1]()
News
Dapagliflozin’s CKD performance sends heart failure messages
October 5, 2020
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians.
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
October 1, 2020
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression.
![1]()
News
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
September 25, 2020
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25.
![1]()
News
Gut bacteria linked to cardiovascular, other health conditions
August 31, 2020
“Microbiota and their metabolites ... could serve as potential therapeutic targets for the maintenance of health and prevention and treatment of cardiovascular diseases.”
